Fluoropyrimidine-induced cardiotoxicity  

作　　者：Andrada Larisa Deac Claudia Cristina Burz Ioana Corina Bocsan Anca Dana Buzoianu 

机构地区：[1]Department of Medical Oncology,"Prof.Dr.Ion Chiricuta"Oncology Institute from Cluj-Napoca,Cluj-Napoca 400015,Cluj,Romania [2]Department of Immunology and Allergology,"Iuliu Hatieganu"University of Medicine and Pharmacy Cluj-Napoca,Cluj-Napoca 400015,Cluj,Romania [3]Department of Pharmacology,Toxicology and Clinical Pharmacology,"Iuliu Hatieganu"University of Medicine and Pharmacy Cluj-Napoca,Cluj-Napoca 400015,Cluj,Romania

出　　处：《World Journal of Clinical Oncology》2020年第12期1008-1017,共10页世界临床肿瘤学杂志（英文版）

摘　　要：Cardio-oncology is a discipline based on early screening,monitoring,and treating chemotherapy-induced cardiotoxicity.There are many chemotherapeutics known for their cardiac toxic effects,including fluoropyrimidines.Fluoropyrimidine represents the cornerstone of many types of cancer and each year almost two million cancer patients undergo this treatment.Fluoropyrimidine-induced cardiotoxicity can be manifested in several forms,from angina pectoris to sudden death.This paper is a review of how the cardiotoxicity of fluoropyrimidines is presented,the mechanisms of its occurrence,its diagnosis,and management.

关 键 词：FLUOROPYRIMIDINES Cancer treatments CARDIOTOXICITY RECHALLENGE PREVENTION ANTIDOTE 

分 类 号：R969[医药卫生—药理学]